199 related articles for article (PubMed ID: 21088503)
1. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
2. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
3. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
4. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
[No Abstract] [Full Text] [Related]
6. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.
Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F
Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387
[TBL] [Abstract][Full Text] [Related]
7. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
[TBL] [Abstract][Full Text] [Related]
9. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract][Full Text] [Related]
10. The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells.
Wang L; Tang L; Yao C; Liu C; Shu Y
J Immunol Res; 2021; 2021():5532269. PubMed ID: 34337076
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
Lu X; Xiao L; Wang L; Ruden DM
Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.
Normann LS; Haugen MH; Hongisto V; Aure MR; Leivonen SK; Kristensen VN; Tahiri A; Engebraaten O; Sahlberg KK; Mælandsmo GM
PLoS One; 2023; 18(1):e0280507. PubMed ID: 36706086
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells.
Zhu H; Zhang G; Wang Y; Xu N; He S; Zhang W; Chen M; Liu M; Quan L; Bai J; Xu N
Cancer Sci; 2010 May; 101(5):1156-62. PubMed ID: 20331626
[TBL] [Abstract][Full Text] [Related]
14. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth.
Liu X; Chipurupalli S; Jiang P; Tavasoli M; Yoo BH; McPhee M; Mazinani S; Francia G; Kerbel RS; Rosen KV
Cell Death Dis; 2022 Aug; 13(8):687. PubMed ID: 35933456
[TBL] [Abstract][Full Text] [Related]
15. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities.
Hu XL; He QW; Long H; Zhang LX; Wang R; Wang BL; Feng JH; Wang Q; Hou JQ; Zhang XQ; Ye WC; Wang H
J Nat Prod; 2021 Jul; 84(7):1954-1966. PubMed ID: 34170694
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
[TBL] [Abstract][Full Text] [Related]
18. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract][Full Text] [Related]
19. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells.
Piven YA; Yastrebova MA; Khamidullina AI; Scherbakov AM; Tatarskiy VV; Rusanova JA; Baranovsky AV; Zinovich VG; Khlebnicova TS; Lakhvich FA
Bioorg Med Chem; 2022 Jan; 53():116521. PubMed ID: 34844036
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor.
Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P
Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]